Suraj Kalia
Stock Analyst at Oppenheimer
(3.32)
# 1,018
Out of 4,732 analysts
83
Total ratings
47.76%
Success rate
3.54%
Average return
Main Sectors:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRTC iRhythm Technologies | Maintains: Outperform | $105 → $120 | $108.33 | +10.77% | 5 | Jan 8, 2025 | |
| TMDX TransMedics Group | Maintains: Outperform | $125 | $57.20 | +118.53% | 9 | Dec 3, 2024 | |
| AORT Artivion | Maintains: Outperform | $30 → $32 | $30.72 | +4.17% | 3 | Nov 8, 2024 | |
| LMAT LeMaitre Vascular | Reiterates: Outperform | $90 → $93 | $99.06 | -6.12% | 2 | Nov 1, 2024 | |
| ATRC AtriCure | Maintains: Outperform | $32 → $36 | $38.47 | -6.42% | 6 | Oct 30, 2024 | |
| ABT Abbott Laboratories | Initiates: Outperform | $130 | $113.48 | +14.56% | 1 | Oct 8, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $10 | $4.93 | +102.84% | 1 | Sep 16, 2024 | |
| EW Edwards Lifesciences | Maintains: Outperform | $90 | $69.78 | +28.98% | 5 | Sep 12, 2024 | |
| NYXH Nyxoah | Maintains: Outperform | $15 → $13 | $10.91 | +19.16% | 4 | Aug 7, 2024 | |
| ITGR Integer Holdings | Initiates: Outperform | $135 | $141.00 | -4.26% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $239.78 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.57 | - | 8 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $30 | $13.52 | +121.89% | 5 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $17.40 | +72.41% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.42 | +2,295.21% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $84.74 | +14.47% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $26.14 | +7.12% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $3.67 | +22.62% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.41 | +262.81% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $592.64 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 | $0.36 | +16,442.60% | 2 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $177.68 | - | 2 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $8.41 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $30.98 | +222.79% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $84.38 | - | 5 | Sep 12, 2018 |
iRhythm Technologies
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $108.33
Upside: +10.77%
TransMedics Group
Dec 3, 2024
Maintains: Outperform
Price Target: $125
Current: $57.20
Upside: +118.53%
Artivion
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $30.72
Upside: +4.17%
LeMaitre Vascular
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $99.06
Upside: -6.12%
AtriCure
Oct 30, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $38.47
Upside: -6.42%
Abbott Laboratories
Oct 8, 2024
Initiates: Outperform
Price Target: $130
Current: $113.48
Upside: +14.56%
TriSalus Life Sciences
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.93
Upside: +102.84%
Edwards Lifesciences
Sep 12, 2024
Maintains: Outperform
Price Target: $90
Current: $69.78
Upside: +28.98%
Nyxoah
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $10.91
Upside: +19.16%
Integer Holdings
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $141.00
Upside: -4.26%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $239.78
Upside: -
Feb 22, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.57
Upside: -
Nov 15, 2023
Maintains: Outperform
Price Target: $42 → $30
Current: $13.52
Upside: +121.89%
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $17.40
Upside: +72.41%
Jun 23, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.42
Upside: +2,295.21%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $84.74
Upside: +14.47%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $26.14
Upside: +7.12%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $3.67
Upside: +22.62%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $4.41
Upside: +262.81%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $592.64
Upside: -
Nov 17, 2020
Upgrades: Outperform
Price Target: $60
Current: $0.36
Upside: +16,442.60%
Nov 3, 2020
Upgrades: Perform
Price Target: n/a
Current: $177.68
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $8.41
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $30.98
Upside: +222.79%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $84.38
Upside: -